Christopher Hite - 18 Aug 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: EVP & Chairman, Partnering
Issuer ticker: RPRX
Reported as of: 18 Aug 2026
Net transaction value: -$5,997,250
SEC form: 4
Accepted by SEC: 19 Aug 2026, 16:20:53 UTC
Prior SEC filing: 07 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite

Key filing fact

Christopher Hite filed Form 4 for Royalty Pharma plc (RPRX) on 19 Aug 2026.

Key facts

This page summarizes Christopher Hite's Form 4 filing for Royalty Pharma plc (RPRX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 Aug 2026, 16:20.

Change

Previous filing in this sequence was filed on 07 Aug 2026.
Current net transaction value: -$5,997,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814238 Primary reporting owner

Hite Christopher

Relationship: EVP & Chairman, Partnering
Address: C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite
Signature date: 19 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPRX transaction

Class A Ordinary Shares

Sale

Transaction value: $5,997,250
Shares: -100,000
Change %: -21%
Price: $59.97
Shares after: 370,401
Date: 18 Aug 2026
Ownership: By SCH Investment Partners LLC
Footnotes: F1, F2

RPRX transaction

Class A Ordinary Shares

Gift

Transaction value
Shares: -16,800
Change %: -42%
Price: $0.000000^*
Shares after: 23,200
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

All reported sales were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.68 to $60.42 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The Reporting Person made a charitable gift of Class A Ordinary Shares to Lehigh University.

SEC remarks

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.